AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $263.34, with a market capitalization of 481.7B. The stock trades at a price-to-earnings (P/E) ratio of 125.47 and offers a dividend yield of 2.65%.
On 2026-07-29, AbbVie(ABBV) stock traded between a low of $262.35 and a high of $267.47. Shares are currently priced at $263.34, which is +0.4% above the low and -1.5% below the high.
AbbVie(ABBV) shares are trading with a volume of 5.56M, against a daily average of 5.52M.
During the past year, AbbVie(ABBV) stock moved between $187.62 at its lowest and $267.47 at its peak.
During the past year, AbbVie(ABBV) stock moved between $187.62 at its lowest and $267.47 at its peak.
ABBV News
Key Points Revolution Medicines has a promising cancer drug in development. Even with this medicine's prospects, the stock's valuation looks too frothy. 10 s...
Key Points AbbVie successfully transitioned away from Humira over the past three years. It still looks cheap relative to its long-term growth potential. It h...
Over the last 7 days, the United States market has experienced a 1.5% decline, although it remains up by 16% over the past year with earnings forecasted to grow...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie recently announced that the European Commission approved RINVOQ (upadacitinib, 15 mg once daily) as the first systemic therapy in the EU for non-segmenta...
AbbVie (ABBV) announced availability of Elahere in Singapore for the treatment of Platinum-Resistant Ovarian Cancer. Elahere is the first and only antibody-drug...
Allergan Aesthetics, an AbbVie company, received European approval for Boey, a botulinum toxin serotype E injectable for glabellar lines. Boey is described as...
Key Points After reporting an earnings beat last quarter, AbbVie could once again beat expectations in the second quarter, although management recently warned...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
Key Points These two companies are pharmaceutical giants. Both seem somewhat overvalued at recent levels. Still, they're likely to do well over the long term...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.